TY  - JOUR
AU  - Partridge, Ann H
AU  - Niman, Samuel M
AU  - Ruggeri, Monica
AU  - Peccatori, Fedro A
AU  - Azim, Hatem A
AU  - Colleoni, Marco
AU  - Saura, Cristina
AU  - Shimizu, Chikako
AU  - Sætersdal, Anna Barbro
AU  - Kroep, Judith R
AU  - Mailliez, Audrey
AU  - Warner, Ellen
AU  - Borges, Virginia F
AU  - Amant, Frédéric
AU  - Gombos, Andrea
AU  - Kataoka, Akemi
AU  - Rousset-Jablonski, Christine
AU  - Borstnar, Simona
AU  - Takei, Junko
AU  - Lee, Jeong Eon
AU  - Walshe, Janice M
AU  - Borrego, Manuel Ruíz
AU  - Moore, Halle Cf
AU  - Saunders, Christobel
AU  - Cardoso, Fatima
AU  - Susnjar, Snezana
AU  - Bjelic-Radisic, Vesna
AU  - Smith, Karen L
AU  - Piccart, Martine
AU  - Korde, Larissa A
AU  - Goldhirsch, Aron
AU  - Gelber, Richard D
AU  - Pagani, Olivia
PY  - 2021
DO  - 10.1016/j.breast.2021.07.021
UR  - http://hdl.handle.net/10668/18376
T2  - Breast (Edinburgh, Scotland)
AB  - Premenopausal women with early hormone-receptor positive (HR+) breast cancer receive 5-10 years of adjuvant endocrine therapy (ET) during which pregnancy is contraindicated and fertility may wane. The POSITIVE study investigates the impact of...
LA  - en
KW  - Breast cancer
KW  - Endocrine therapy
KW  - Pregnancy desire
KW  - Premenopausal women
KW  - Treatment interruption
KW  - Young women
KW  - Adult
KW  - Antineoplastic Agents, Hormonal
KW  - Breast Neoplasms
KW  - Cancer Survivors
KW  - Chemotherapy, Adjuvant
KW  - Female
KW  - Hormones
KW  - Humans
KW  - Mastectomy
KW  - Pregnancy
KW  - Premenopause
KW  - Tamoxifen
TI  - Who are the women who enrolled in the POSITIVE trial: A global study to support young hormone receptor positive breast cancer survivors desiring pregnancy.
TY  - research article
VL  - 59
ER  -